Outlook Therapeutics has submitted its BLA to the U.S. FDA for ONS-5010, an investigational ophthalmic formulation of bevacizumab, for treatment of wet AMD. ONS-5010, if approved, is expected to receive 12 years of marketing exclusivity. ir.outlooktherapeutics.com/news-releases/… #wetAMD $OTLK
